Navigation Links
Independent Data Monitoring Committee Supports Continuation of Picoplatin Phase 3 SPEAR Registration Trial in Small Cell Lung Cancer
Date:5/5/2009

SOUTH SAN FRANCISCO, Calif., May 5 /PRNewswire-FirstCall/ -- Poniard Pharmaceuticals, Inc. (Nasdaq: PARD) today announced that the independent Data Monitoring Committee (DMC), after review of available information regarding the efficacy, safety and quality of trial conduct, recommends that the SPEAR (Study of Picoplatin Efficacy After Relapse) trial continue. The international, pivotal Phase 3 trial is evaluating the efficacy and safety of picoplatin in patients with small cell lung cancer (SCLC) who were refractory to or progressed within six months of first-line therapy.

"The recommendation by the DMC to continue our SCLC registration trial represents another milestone in the development of picoplatin as a potential new treatment option for SCLC patients," said Jerry McMahon, Ph.D., chairman and chief executive officer of Poniard. "We are encouraged by the continued progress of the trial and remain on track to complete the clinical data analysis to support the initiation of a New Drug Application with the U.S. Food and Drug Administration this year."

About the Independent DMC

The DMC is an independent, multi-disciplinary group consisting of clinicians and a biostatistician that, collectively, have experience in the management of patients with SCLC and in the conduct and monitoring of randomized clinical trials. The DMC is responsible for safeguarding the interests of the SPEAR trial participants, assessing the safety and efficacy of the interventions during the trial, and for monitoring the overall conduct of the clinical trial. To contribute to enhancing the integrity of the trial, the DMC will also review whether Best Supportive Care (BSC) is qualitatively or quantitatively adequate or inadequate within and between the treatment arms.

Phase 3 SPEAR Trial Design and Special Protocol Assessment
'/>"/>

SOURCE Poniard Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. 3SBio Inc. Announces Appointment of Ernst & Young Hua Ming as Independent Auditor
2. Concerned Shareholders of Biovail Announce - Independent Nominees for Election to Biovail Board of Directors - A Focused Commitment to Governance at Biovail
3. Spherix Recruiting New Independent Director to Regain NASDAQ Compliance
4. Independent Study Corroborates Pranas Strategy to Treat Alzheimers Disease Patients.
5. Virginia Tech engineers investigate energy independent monitoring system for bridges
6. Immtech Announces Appointment of Virchow Krause as Independent Registered Public Accounting Firm
7. French Agency AMP Appoints Dr Kamel Senouci as Director of SIVAC Initiative (Supporting Independent Immunization and Vaccine Advisory Committees)
8. Major Independent Study Underscores Utility of deCODE MI(TM) for Better Predicting Risk of Heart Attack, Informing Statin Therapy
9. ProtoKinetix Receives Independent Confirmation of AAGP Anti-Inflammatory Action
10. Independent Study Reveals SYNVISC(R) Offers Longer Knee Pain Relief and Greater Patient Satisfaction for Those Suffering from Osteoarthritis of the Knee
11. Independent Monitoring Board Recommends Completion of Accrual to Genasense(R) Phase 3 AGENDA Trial in Advanced Melanoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2015)... - New Massive Open Online Course (MOOC) ... United States Medical Licensing Examination Elsevier ... information products and services, announced today that it has ... to help medical students prepare for the United States ... most daunting of the three exams medical students must ...
(Date:5/1/2015)...  Northwest Biotherapeutics (NASDAQ: NWBO ) ("NW Bio"), ... for solid tumor cancers, announced today that the Company ... a $40 million investment from Woodford investment funds in ... million in NW Bio on November 19, 2014.  On ... the Company for a further $40 million investment in ...
(Date:5/1/2015)... A new report by  visiongain ... reach $22.4bn in 2019. That revenue forecast and others ... Prospects 2015-2025 ,  published in March 2015. ... provide forecasts and qualitative analyses of the antithrombotic drugs ... in London, UK . It produces ...
(Date:4/30/2015)... Carolina (PRWEB) May 01, 2015 Spirax ... services, is extremely proud to announce that for the ... named as a winner of a Queen’s Award for ... for the design and manufacture of a unique flowmeter. ... the revolutionary alternative to traditional steam flow measurement. ...
Breaking Biology Technology:Elsevier's Free MOOC Prepares Med Students for Licensing Exam 2Elsevier's Free MOOC Prepares Med Students for Licensing Exam 3NW Bio Closes On $28.5 Million Second Tranche Of Woodford $40 Million Financing 2NW Bio Closes On $28.5 Million Second Tranche Of Woodford $40 Million Financing 3Antithrombotic Drugs: World Industry and Market Prospects 2015-2025 2Antithrombotic Drugs: World Industry and Market Prospects 2015-2025 3Antithrombotic Drugs: World Industry and Market Prospects 2015-2025 4Antithrombotic Drugs: World Industry and Market Prospects 2015-2025 5Spirax Sarco Receives a Queen’s Award for Innovation 2Spirax Sarco Receives a Queen’s Award for Innovation 3
... to $245 Million to $247 Million -, Third Quarter 2008 Highlights:, ... quarter of 2007 -- Total revenues without Osteocel of $62.5 million; ... -- Gross profit of $54.7 million; up 73.2% from the ... to 82.0% in the third quarter of 2007, -- GAAP ...
... Sangamo,BioSciences, Inc. (Nasdaq: SGMO ) today announced that ... on Wednesday, October 29,2008, after the market closes. The ... 5:00 p.m. ET, which will be open to the ... company will review,the financial results and discuss other business ...
... Oct. 22 MaxCyte, Inc., the pioneer,in scalable, ... will,be launching the MaxCyte STX Scalable Transfection System ... Based Assays: Innovations,in Reagents, Technology, and Screening," to ... and Friday, October 23-24, 2008. In addition, MaxCyte ...
Cached Biology Technology:Nuvasive Reports Third Quarter 2008 Financial Results 2Nuvasive Reports Third Quarter 2008 Financial Results 3Nuvasive Reports Third Quarter 2008 Financial Results 4Nuvasive Reports Third Quarter 2008 Financial Results 5Nuvasive Reports Third Quarter 2008 Financial Results 6Nuvasive Reports Third Quarter 2008 Financial Results 7Nuvasive Reports Third Quarter 2008 Financial Results 8Nuvasive Reports Third Quarter 2008 Financial Results 9Nuvasive Reports Third Quarter 2008 Financial Results 10Nuvasive Reports Third Quarter 2008 Financial Results 11Nuvasive Reports Third Quarter 2008 Financial Results 12Sangamo BioSciences Announces Third Quarter Conference Call and Webcast 2Sangamo BioSciences Announces Third Quarter Conference Call and Webcast 3The MaxCyte STX Scalable Transfection System to be Launched at the SBS Symposium on Cell-Based Assays 2
(Date:3/24/2015)... , March 24, 2015   Crossmatch ... solutions, today announced that its U.are.U ® ... retailer Goorin Bros . to achieve PCI ... solution secures access to the POS terminal, protecting ... risk of data breaches. With ...
(Date:3/23/2015)... NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or the ... commerce market, announces its biometric payment technology, the Wocket® smart ... starting March 30 th . The ... New York markets. Gino ... our new ad campaign following the recent initial shipment of ...
(Date:3/20/2015)... 2015 Research and Markets ( http://www.researchandmarkets.com/research/vkzvcs/iris_biometrics ) ... Global Strategic Business Report" report to their offering. ... in US$ Thousands. The report provides separate comprehensive analytics for ... , Europe , Asia-Pacific ... Latin America . Annual estimates and ...
Breaking Biology News(10 mins):Crossmatch Fingerprint Readers Help Retailer Prevent Data Breaches at Point-of-Sale 2NXT-ID's Wocket Smart Wallet to Launch New CNBC Regional TV Ad Campaign 2NXT-ID's Wocket Smart Wallet to Launch New CNBC Regional TV Ad Campaign 3Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 2Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 3Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 4Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 5
... 12 Orchid Cellmark Inc.,(Nasdaq: ORCH ) today ... of Orchid, is scheduled to present at the 2008 ... Wednesday, May 14, 2008 at,3:20 p.m. PDT., Mr. ... the,company,s recent and ongoing progress. A link to the ...
... most attractive male birds attract more females and as a ... the starting point of many studies looking for factors that ... assume that birds see what we see? In a study ... show that our human vision is not an adequate instrument. ...
... taken two unlikely distant cousins turkeys and scallops - ... University of Leeds researchers have found that a motor protein, ... , The discovery suggests that the tiny motor protein ... humans it may even hold a key to understanding potentially ...
Cached Biology News:Human vision inadequate for research on bird vision 2Ancient protein offers clues to killer condition 2
Human/Mouse APLP-1 MAb (Clone 354020) ENTREZ GeneID: 333...
Mouse monoclonal [Flt-1/EWC] to VEGF Receptor 1 ( Abpromise for all tested applications). entrezGeneID: 2321 SwissProtID: P17948...
Mitotic Kinesin-Like Protein 1 (MKLP-1, KNSL5)...
Mouse Anti-Human MCAF-(MCP-1)...
Biology Products: